Original price was: £43.90.£34.95Current price is: £34.95.
Original price was: £43.90.£34.95Current price is: £34.95.
BUY 2, SAVE 5%
£34.95 £33.20 / ITEM
BUY 3, SAVE 10%
£34.95 £31.46 / ITEM
BUY 4, SAVE 15%
£34.95 £29.71 / ITEM
33 in stock
CJC-1295 (No DAC) / Ipamorelin Blend is a combination of 5 mg CJC-1295 (modified GRF 1-29) and 5 mg Ipamorelin in one lyophilised vial.
The combination is often used in research, since the peptides stimulate the release of the growth hormone via different biological pathways. CJC-1295 (no DAC) is a modified analogue of growth hormone-releasing hormone (GHRH). Ipamorelin is a selective growth hormone secretagogue (GHS) which activates the ghrelin (GHS-R1a) receptor.
The peptides have been shown to have additive effects on endogenous growth hormone release in experimental models through targeting different receptors on pituitary somatotroph cells. Unlike exogenous HGH, neither peptide contains growth hormone itself but rather stimulates the body’s own physiological release mechanisms.
The No DAC version of CJC-1295 is designed to produce a short GH pulse that is more consistent with normal physiology and is therefore preferred in many research protocols studying recovery, body composition, sleep quality and tissue repair.
This product is for laboratory and scientific research use only, not for human consumption.
For Research Use Only – Not Intended for Medical Use
The CJC-1295 (No DAC) / Ipamorelin blend is often researched when taken twice a day to coincide with the body’s natural periods of elevated growth hormone release.
Standard Research Protocol
Dose: 100 mcg CJC-1295 + 100 mcg Ipamorelin
How Often: 1-3 times daily
Common timing:
Straight out of bed
Training (optional)
30-60 minutes before bed
Administration:
Subcutaneous injection.
Upper arm, abdomen, or thigh
Injection site rotation
Duration: Usually 8-16 weeks. Depending on the objectives of the study, there are some studies that go beyond this.
Researchers generally recommend that you not eat about 30 to 60 minutes before and after the administration, especially meals high in carbohydrates, because high levels of insulin may blunt endogenous GH secretion.
| Tier | Dosage | Frequency | Notes |
|---|---|---|---|
| Weeks 1-16 | 200mcg (100mcg of each) | 1-3 times daily | Straight out of bed Training (optional) 30-60 minutes before bed |
Published studies and observational reports suggest the combination may be worth investigating for:
A lot of researchers like to combine CJC-1295 (No DAC) with Ipamorelin because the two compounds stimulate GH release via complementary receptor pathways and do not compete for the same receptor.
CJC-1295 (No DAC) / Ipamorelin Blend This blend has attracted considerable research interest as the combination of two peptides that stimulate the release of endogenous growth hormone by a variety of complementary biological mechanisms.
CJC-1295 (No DAC) is a modified analogue of Growth Hormone Releasing Hormone (GHRH). It is a GHRH receptor agonist at the anterior pituitary level, inducing the pulsatile release of growth hormone in a more physiological pattern.
Ipamorelin is a very selective Growth Hormone Secretagogue (GHS) It binds to the ghrelin (GHS-R1a) receptor rather than stimulating GHRH receptors. This provides a separate stimulus for growth hormone secretion and causes minimal effects on cortisol and prolactin compared to earlier generations of GHRPs.
In research, the two peptides are thought to produce a greater growth hormone response together because they activate different receptor systems that are involved in GH regulation. The subsequent increase in endogenous growth hormone stimulates the liver to produce Insulin-like Growth Factor-1 (IGF-1), a hormone involved in a multitude of anabolic and regenerative processes.
Researchers have investigated this pathway for its possible role in:
CJC-1295 (No DAC) and Ipamorelin do not contain any growth hormone of their own unlike recombinant human growth hormone (HGH). Instead, they are screened for their ability to encourage the body’s own physiological release patterns.
Reported side effects may include the following, but in published studies it is generally considered to be well tolerated:
The effects reported are generally mild and temporary.
Studies of growth hormone secretagogues generally take into account lifestyle factors that naturally affect endogenous GH production. Control of these factors may decrease variability in experimental models.
Important considerations are:
Rest
The largest natural GH pulse generally occurs during deep sleep. So consistent sleep duration and quality are important variables in studies with CJC-1295 and Ipamorelin.
Nutritional
Nutrient intake, especially blood glucose and insulin, influences growth hormone secretion. Some research protocols standardise the fasting period around dosing, because high carbohydrate meals consumed just before dosing may reduce the magnitude of endogenous GH release.
Adequate dietary protein is also important when considering changes in recovery, lean mass or muscle protein synthesis.
Strength Training
Exercise is a potent natural stimulus to growth hormone secretion. In many studies of GH-related peptides, structured resistance training programmes are employed to investigate interactions between hormonal responses to exercise and peptide administration.
Rehabilitation
All recovery variables including rest days, hydration, stress management and sleep quality can affect anabolic signalling and should be considered when interpreting research outcomes.
Body Composition
Endogenous growth hormone secretion may be influenced by factors such as insulin sensitivity, body-fat percentage, age and baseline IGF-1 levels. Commonly controlled or measured in clinical and pre-clinical research these variables are used to improve consistency among subjects.
Consistency of Study
Research protocols often try to control for variability by standardising things like timing of administration, meals, exercise, and sleep over the course of the study period. If the experimental conditions are kept constant , any changes seen can more confidently be ascribed to the intervention under investigation .
Looking for Weight Loss Peptides?
Explore Weight Loss Peptides with our trusted partner
If you can't find the product you're looking for here, visit Biovanta Research a premium range of weight loss research peptides.
